Ovarian, Fallopian Tube or Peritoneal Cancer Treatment Study
This trial studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating women with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not known yet whether olaparib or cediranib maleate and olaparib are more effective than standard platinum-based chemotherapy in treating patients with platinum-sensitive cancer.
In order to participate you must meet the following criteria:
- Have platinum-sensitive (responsive to platinum-based chemotherapy) high-grade serous or endometrioid ovarian, primary peritoneal or fallopian tube cancer that has returned.
- Have adequate organ and bone marrow function.
- Are able to swallow pills.
- Are willing and able to check and record daily blood pressure readings.
You will be excluded from the study if any of the following criteria apply to you:
- Have had chemotherapy or radiotherapy within 4 weeks of starting treatment.
- Have received any other investigational agents or participated in an investigational trial within the past 4 weeks.
- Have previously received a PARP-inhibitor (such as olaparib, veliparib or naraparib).
- Have uncontrolled intercurrent illness, such as on ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with any study requirements.
This is a partial list of inclusion and exclusion criteria.